American Thoracic Society - Sanofi Investor Call

Background 50% of patients continue to have persistent symptoms and exacerbations despite optimization of existing therapy COPD exacerbations are associated with: ○ Increased risk of subsequent exacerbations o Lung function decline o High morbidity and increased risk of all-cause mortality A subgroup of COPD patients have an unmet need for therapies that further reduce exacerbations and improve lung function ATS 2023 15 15

View entire presentation